A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia

Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Gohei Yagi, Haruo Kashima

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Second-generation antipsychotic medications have become popular as a treatment for schizophrenia. The authors investigated 25 chronic subjects who had previously been treated with high-dose antipsychotic polypharmacy without amelioration. All patients had a history of having been treated with an antipsychotic polypharmacy regimen of the total daily chlorpromazine equivalent dose exceeding 1000 mg/day for more than 6 weeks. They were subsequently switched to a second-generation antipsychotic monotherapy. Other psychotropic medications were simplified at the same time. For successful patients whose symptoms showed at least minimal improvement, the medical chart was reviewed retrospectively. After completed switching, the patients were followed up for 12 weeks, when final evaluation was made. The Global Assessment of Functioning score improved from 32 to 47. The number of antipsychotic medications and total psychotropic medications were significantly reduced from 3.5 to 1.1 and 6.8 to 2.6, respectively. Also, the antipsychotic dose was significantly minimized from 2203 to 619 mg/day. Eleven of eighteen inpatients were discharged and the other four were better enough to be ready for discharge. By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain.

Original languageEnglish
Pages (from-to)361-369
Number of pages9
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume28
Issue number2
DOIs
Publication statusPublished - 2004 Mar

Fingerprint

Polypharmacy
Proxy
Antipsychotic Agents
Schizophrenia
Chlorpromazine
Inpatients

Keywords

  • Antipsychotic monotherapy
  • Antipsychotic polypharmacy
  • High-dose therapy
  • Schizophrenia
  • Switching

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. / Suzuki, Takefumi; Uchida, Hiroyuki; Watanabe, Koichiro; Yagi, Gohei; Kashima, Haruo.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, No. 2, 03.2004, p. 361-369.

Research output: Contribution to journalArticle

@article{ef7a7b33cecf4ff2aa62a84a8039c2ca,
title = "A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia",
abstract = "Second-generation antipsychotic medications have become popular as a treatment for schizophrenia. The authors investigated 25 chronic subjects who had previously been treated with high-dose antipsychotic polypharmacy without amelioration. All patients had a history of having been treated with an antipsychotic polypharmacy regimen of the total daily chlorpromazine equivalent dose exceeding 1000 mg/day for more than 6 weeks. They were subsequently switched to a second-generation antipsychotic monotherapy. Other psychotropic medications were simplified at the same time. For successful patients whose symptoms showed at least minimal improvement, the medical chart was reviewed retrospectively. After completed switching, the patients were followed up for 12 weeks, when final evaluation was made. The Global Assessment of Functioning score improved from 32 to 47. The number of antipsychotic medications and total psychotropic medications were significantly reduced from 3.5 to 1.1 and 6.8 to 2.6, respectively. Also, the antipsychotic dose was significantly minimized from 2203 to 619 mg/day. Eleven of eighteen inpatients were discharged and the other four were better enough to be ready for discharge. By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain.",
keywords = "Antipsychotic monotherapy, Antipsychotic polypharmacy, High-dose therapy, Schizophrenia, Switching",
author = "Takefumi Suzuki and Hiroyuki Uchida and Koichiro Watanabe and Gohei Yagi and Haruo Kashima",
year = "2004",
month = "3",
doi = "10.1016/j.pnpbp.2003.11.006",
language = "English",
volume = "28",
pages = "361--369",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia

AU - Suzuki, Takefumi

AU - Uchida, Hiroyuki

AU - Watanabe, Koichiro

AU - Yagi, Gohei

AU - Kashima, Haruo

PY - 2004/3

Y1 - 2004/3

N2 - Second-generation antipsychotic medications have become popular as a treatment for schizophrenia. The authors investigated 25 chronic subjects who had previously been treated with high-dose antipsychotic polypharmacy without amelioration. All patients had a history of having been treated with an antipsychotic polypharmacy regimen of the total daily chlorpromazine equivalent dose exceeding 1000 mg/day for more than 6 weeks. They were subsequently switched to a second-generation antipsychotic monotherapy. Other psychotropic medications were simplified at the same time. For successful patients whose symptoms showed at least minimal improvement, the medical chart was reviewed retrospectively. After completed switching, the patients were followed up for 12 weeks, when final evaluation was made. The Global Assessment of Functioning score improved from 32 to 47. The number of antipsychotic medications and total psychotropic medications were significantly reduced from 3.5 to 1.1 and 6.8 to 2.6, respectively. Also, the antipsychotic dose was significantly minimized from 2203 to 619 mg/day. Eleven of eighteen inpatients were discharged and the other four were better enough to be ready for discharge. By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain.

AB - Second-generation antipsychotic medications have become popular as a treatment for schizophrenia. The authors investigated 25 chronic subjects who had previously been treated with high-dose antipsychotic polypharmacy without amelioration. All patients had a history of having been treated with an antipsychotic polypharmacy regimen of the total daily chlorpromazine equivalent dose exceeding 1000 mg/day for more than 6 weeks. They were subsequently switched to a second-generation antipsychotic monotherapy. Other psychotropic medications were simplified at the same time. For successful patients whose symptoms showed at least minimal improvement, the medical chart was reviewed retrospectively. After completed switching, the patients were followed up for 12 weeks, when final evaluation was made. The Global Assessment of Functioning score improved from 32 to 47. The number of antipsychotic medications and total psychotropic medications were significantly reduced from 3.5 to 1.1 and 6.8 to 2.6, respectively. Also, the antipsychotic dose was significantly minimized from 2203 to 619 mg/day. Eleven of eighteen inpatients were discharged and the other four were better enough to be ready for discharge. By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain.

KW - Antipsychotic monotherapy

KW - Antipsychotic polypharmacy

KW - High-dose therapy

KW - Schizophrenia

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=1642482327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642482327&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2003.11.006

DO - 10.1016/j.pnpbp.2003.11.006

M3 - Article

C2 - 14751434

AN - SCOPUS:1642482327

VL - 28

SP - 361

EP - 369

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -